Using Antiseptic Mouthrinses to Reduce Sars-Cov2 Oral Viral Load
Full Text (PDF)
Michele Benegiamo 1, Angelo Sammarro 2 * , Edoardo Rella 1 , Antonio D'Addona 3, Franklin Garcia-Godoy 4 5
More Detail
1 Department of Head and Neck, Oral Surgery and Implantology Unit, Institute of Clinical Dentistry, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ITALY2 Department of Applied Pharmaceutical Sciences – Quality Control, Università Degli Studi di Firenze, Firenze, ITALY3 Professor and Head, Department of Head and Neck, Oral Surgery and Implantology Unit, Institute of Clinical Dentistry, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ITALY4 Professor and Director, Bioscience Research Center, College of Dentistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA5 Senior Clinical Investigator, The Forsyth Center, Cambridge, Massachusetts, USA* Corresponding Author

Abstract

Virucidal activity of Povidone-Iodine (PVP-I) have not yet been performed specifically on SARS-CoV-2. There have been in vitro studies demonstrating its effectiveness against multiple viruses including related coronaviruses. PVP-I could be effective to reduce viral load from asymptomatic COVID-19 patients and also provide a protective oropharyngeal hygiene measure for the health professionals.

Keywords

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Short Communication

ELECTRON J GEN MED, Volume 18, Issue 1, February 2021, Article No: em273

https://doi.org/10.29333/ejgm/9616

Publication date: 20 Jan 2021

Article Views: 1891

Article Downloads: 1809

Open Access References How to cite this article